Full-Time

Director of AI Engineering

Vaccine R&D Operations Enablement

Updated on 7/25/2026

Pfizer

Pfizer

10,001+ employees

Biopharmaceutical company develops medicines and vaccines

Compensation Overview

$176.6k - $294.3k/yr

+ Bonus (20% of base) + Long-term incentive program (share-based)

No H1B Sponsorship

New City, NY, USA

Hybrid

Hybrid role; 2.5 on-site days per week within commuting distance.

Category
Engineering Management (1)
Required Skills
MLOps
Python
Tensorflow
Pytorch
Machine Learning

Get referred to Pfizer

Find people who can refer or advise you

Requirements
  • PhD in Computer Science, Machine Learning, Data Science, Software Engineering, AI, or a related discipline and a minimum of 5 years of applied analytical experience with demonstrated impact in operations, automation, business analytics, or decision support
  • Master’s in Computer Science, Machine Learning, Data Science, Software Engineering, AI, or a related discipline and a minimum of 7 years of applied analytical experience with demonstrated impact in operations, automation, business analytics, or decision support
  • Minimum 2 years of AI/ML experience in a relevant domain
  • Strong understanding of process-heavy environments, ideally within R&D, clinical operations or large-scale regulated organizations
  • Expertise in predictive modeling, optimization, automation, generative AI, and ML system design
  • Strong programming skills in Python and modern ML frameworks (e.g., PyTorch, TensorFlow), plus experience scaling models in cloud and/or HPC environments
  • Experience collaborating across scientific, operational, quality, and business teams, translating complex needs into practical AI solutions
  • Clear communication skills
Responsibilities
  • Define and deliver AI solutions that support process-heavy lab and office workflows, including experiment tracking, documentation, handoffs, and operational reporting
  • Drive automation of manual and repetitive activities to improve speed, quality, consistency, and compliance across vaccine development
  • Develop predictive, optimization, and scenario-based models to support resource planning, capacity management, timeline forecasting, and risk trade-offs
  • Develop dashboards and decision-support tools that translate complex operational data into actionable insights for R&D and leadership teams
  • Design AI solutions aligned with GxP expectations, data integrity standards, and inspection readiness, supporting deviation monitoring, CAPA trending, documentation completeness, data genealogy, and audit preparedness
  • Establish governance models covering model validation, versioning, explainability, monitoring, and lifecycle management in regulated environments
  • Build AI-enabled capabilities for development planning, milestone tracking, dependency management, and execution risk forecasting across the vaccine development lifecycle
  • Lead process optimization and reengineering initiatives, using AI, automation, and data-driven methods to simplify workflows and reduce cycle times
  • Architect and deploy robust, production-ready ML and analytics pipelines with appropriate governance, reproducibility, and monitoring
  • Scale AI solutions in cloud and/or High-Performance Computing environments, ensuring reliability, security, and seamless integration with existing R&D, financial, and operational systems
  • Act as a strategic bridge between technical teams and scientific, operational, quality, and business stakeholders to ensure adoption and measurable value
  • Mentor engineers and operational partners, raising AI and data literacy across vaccine R&D
  • Champion best practices in MLOps, software engineering, and AI system lifecycle management
Desired Qualifications
  • Experience in life sciences, pharma, R&D, clinical operations, or other regulated industries
  • Financial and business experience supporting budgets, forecasting, vendor management, or portfolio analytics

Pfizer is a global biopharmaceutical company that discovers, develops, manufactures, and sells medicines and vaccines for a range of health needs, including vaccines, oncology, and other specialized therapies. Its products work by using biological mechanisms to prevent or treat diseases—vaccines train the immune system to fight infections, while medicines target cancer and other conditions. Pfizer differentiates itself through its large worldwide footprint, broad portfolio across multiple therapeutic areas, and partnerships (notably with BioNTech) that expanded its reach in vaccines and cutting-edge therapies. The company also engages in public health initiatives, such as efforts to provide vaccines to underserved populations. Pfizer’s broad goal is to improve global health by delivering safe and effective medicines and vaccines through research, development, and wide international distribution.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1849

Get referred to Pfizer

Find people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Obesity asset MET097i targets 2028 launch to offset $17B–$18B patent cliff losses.
  • Oncology revenues grew 7% to $3.8B in Q1 2026, driven by Padcev and Lorbrena.
  • FDA approval for Padcev-Keytruda expands bladder cancer treatment to earlier disease stages.

What critics are saying

  • Eliquis, Ibrance, Xtandi, and Prevnar 13 lose exclusivity by 2028, dropping $17B revenue.
  • Sigvotatug vedotin failed Phase 3 for lung cancer, weakening Seagen's oncology pipeline de-risking.
  • Cash flow fell $700M short of covering dividends in 2025, pressuring the 7% yield.

What makes Pfizer unique

  • Pfizer leads with four marketed antibody-drug conjugates from its $43B Seagen acquisition.
  • The company offers a monthly GLP-1 obesity drug, berobenatide, from Metsera.
  • Patent-protected Padcev-Keytruda regimen is the first platinum-free option for bladder cancer.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Hybrid Work Options

Relocation Assistance

Growth & Insights and Company News

Headcount

6 month growth

-2%

1 year growth

-2%

2 year growth

-2%
Pfizer
May 4th, 2026
Esperion Therapeutics Completes $22.75 M Series A Financing | Pfizer

ANN ARBOR, Mich. & NEW YORK--(BUSINESS WIRE)--ANN ARBOR, Mich

Yahoo Finance
Apr 9th, 2026
Pfizer beats Q4 revenue estimates by 5.5% as branded pharma sector faces mixed earnings

Ten branded pharmaceuticals stocks reported mixed fourth-quarter results, with revenues missing analysts' consensus estimates by 1.7% on average. Share prices have declined 3% on average since the latest earnings results. Pfizer reported revenues of $17.56 billion, down 1.2% year-on-year but exceeding analysts' expectations by 5.5%. The stock has risen 2.8% since reporting and currently trades at $27.40. Eli Lilly delivered the strongest performance amongst peers, reporting revenues of $19.29 billion, up 42.6% year-on-year and beating expectations by 7.4%. Despite the impressive results, shares have fallen 5.2% since reporting to $951.77. The industry faces tailwinds from precision medicine advances and AI adoption, but headwinds include regulatory scrutiny, pricing pressures and patent cliffs for blockbuster drugs.

Yahoo Finance
Apr 7th, 2026
Pfizer stock seen as undervalued buy despite pipeline growth and strategic acquisitions

Pfizer, trading at less than 10 times estimated future earnings, presents significant upside potential despite recent revenue declines. The pharmaceutical company's sales fell from $101 billion in 2022 to under $63 billion last year as COVID-19 product revenues diminished. However, Pfizer has been actively preparing for growth through strategic acquisitions. In 2023, it purchased oncology specialist Seagen for $43 billion, gaining access to promising antibody-drug conjugates for cancer treatment. Last year, it acquired GLP-1 drugmaker Metsera for up to $10 billion to enter the anti-obesity drug market. The company maintains over 100 drug candidates in development. Whilst facing near-term patent cliffs on key drugs, Pfizer's extensive pipeline and low valuation suggest substantial long-term potential for investors willing to accept calculated risk.

Yahoo Finance
Apr 6th, 2026
Pfizer shares climb 7.1% in six months as organic revenue grows 10.1% annually

Pfizer shares have climbed to $28.30, delivering a 7.1% return over the past six months and outperforming the S&P 500 by 9.4 percentage points. The pharmaceutical company's organic revenue has grown at a solid 10.1% year-on-year average over the last two years, whilst its adjusted operating margin rose 17.8 percentage points to reach 35.1% for the trailing 12 months. However, Pfizer's long-term performance shows slower growth, with revenue expanding at just a 5.6% compound annual growth rate over the past five years, underperforming the broader healthcare sector. The stock currently trades at 9.6× forward price-to-earnings ratio. Founded in 1849, Pfizer develops and manufactures medicines and vaccines for various diseases and conditions globally.

Yahoo Finance
Mar 30th, 2026
Pfizer shares up 25% since Jim Cramer said 'pass' on Mad Money

Pfizer shares have risen 25% since Jim Cramer advised investors to "pass" on the stock in April 2025, citing uncertainty over potential tariffs and taxes on pharmaceutical companies. The shares are up 6.7% over the past year and 7.4% year-to-date. A notable gain occurred between 29 September and 1 October, when shares jumped 14% following Pfizer's announcement that it would lower Medicaid drug prices to match those in developing countries as part of the Trump administration's TrumpRx initiative. However, shares fell 3.3% on 3 February after the company reported fourth-quarter results of $17.6 billion in revenue and $0.66 adjusted earnings per share. Pfizer is developing a once-monthly weight loss treatment and currently offers an 8% dividend yield.